Stock Research Monitor: AMDA, AXGN, and CVRS
LONDON, UK / ACCESSWIRE / June 27, 2018 / If you want a free Stock Review on AVGR sign up now at www.wallstequities.com/registration. Pre-market today, WallStEquities.com scans the following Medical Appliances and Equipment stocks: Amedica Corp. (NASDAQ: AMDA), Avinger Inc. (NASDAQ: AVGR), AxoGen Inc. (NASDAQ: AXGN), and Corindus Vascular Robotics Inc. (NYSE AMER: CVRS). These equities belong to the healthcare sector, which is made up of companies that specialize in products and services related to health and medical care. All you have to do is sign up today for this free limited time offer by clicking the link below.
Salt Lake City, Utah headquartered Amedica Corp.'s stock finished Tuesday's session 2.86% higher at $1.08 with a total trading volume of 256,544 shares. The stock is trading below their 50-day moving average by 12.58%. Shares of the Company, which develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the US, Europe, and South America, have a Relative Strength Index (RSI) of 49.59. Get the full research report on AMDA for free by clicking below at:
Shares in Redwood City, California headquartered Avinger Inc. ended at $1.87, up 16.11% from the last trading session. The stock recorded a trading volume of 8.82 million shares, which was above its three months average volume of 1.95 million shares. The Company's shares have gained 58.47% in the previous three months. The stock is trading 25.72% above its 50-day moving average. Moreover, shares of Avinger, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the US and Europe, have an RSI of 62.14.
On June 21st, 2018, Avinger announced that its Ocelot image-guided chronic total occlusion (CTO) crossing device was featured in a live case at the Complex Cardiovascular Catheter Therapeutics 2018, which was held on June 19th, 2018, in Orlando, Florida. Ocelot combines real-time image guidance using optical coherence tomography, with a proprietary CTO crossing catheter design to aid physicians in the treatment of chronic total occlusions. Gain free access to the research report on AVGR at:
Alachua, Florida headquartered AxoGen Inc.'s stock ended yesterday's session 3.87% higher at $51.00. A total volume of 709,917 shares was traded, which was above their three months average volume of 421,110 shares. The Company's shares have advanced 12.46% in the past month, 28.30% over the previous three months, and 238.87% over the past year. The stock is trading 13.63% and 62.57% above its 50-day and 200-day moving averages, respectively. Additionally, shares of AxoGen, which develops and markets surgical solutions for peripheral nerve injuries, have an RSI of 60.67.
On June 04th, 2018, AxoGen announced the appointment of Kaila Krum to the newly created position of Vice President - Investor Relations and Corporate Development, effective immediately. In this new role, Ms. Krum will support and advance the Company's investor relations program, focused on educating the financial community about its platform for nerve repair, strategic growth plans, and business execution. She reports directly to Peter J. Mariani, CFO.Signing up today on Wall St. Equities will give you access to the latest report on AXGN at:
Corindus Vascular Robotics
On Tuesday, shares in Waltham, Massachusetts headquartered Corindus Vascular Robotics Inc. recorded a trading volume of 2.82 million shares, which was above their three months average volume of 1.12 million shares. The stock finished 17.73% higher at $0.86. The Company's shares have advanced 9.01% in the last month. The stock is trading below its 50-day moving average by 4.27%. Furthermore, shares of the Company, which designs, manufactures, and sells robotic-assisted precision vascular systems for use in interventional vascular procedures in the US and internationally, have an RSI of 53.73.
On June 19th, 2018, Corindus Vascular Robotics announced that it has appointed Douglas Teany, who is currently the Company's Senior Vice President of R&D and Operations, to COO, effective immediately. Mr. Teany brought eighteen years of experience to the Company, driving operational excellence in the medical device and pharmaceutical industries.Register now for today's free coverage on CVRS at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities